ERBB2 S310F/Y

CI-VAR-00004047Explore in graph →ENST00000269571.5:c.929C>TClinVar 376189 CIViC 497

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colon Neoplasm1
ERBB2 S310F/Y	Lapatinib + Neratinib + TrastuzumabCombination	Predictive	D	Supports Sensitivity Response	4	accepted	EID1179 Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with tras… (full text at CIViC) PMID 26243863 · Kavuri et al., 2015 · Open in CIViC	civic
Malignant Colorectal Neoplasm1
ERBB2 S310F/Y	Cetuximab	Predictive	D	Supports Resistance	—	submitted	EID4518 bp]In an in vitro study, NCI-H508 cell lines expressing an ERBB2 S310F mutation demonstrated resistance to cetuximab treatment, compared to NCI-H508 cells expressing ERBB2 wild-type. Resistance was de…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.